4.7 Article

CDKL5 is a brain MeCP2 target gene regulated by DNA methylation

Journal

NEUROBIOLOGY OF DISEASE
Volume 38, Issue 3, Pages 414-424

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2010.02.014

Keywords

Rett syndrome; Neurodevelopmental disorders; Drug of abuse; Epigenetics; DNA methylation; Chromatin remodeling; MeCP2

Categories

Funding

  1. INSERM
  2. Universite de Strasbourg
  3. Association Francaise du Syndrome de Rett (AFSR)
  4. Ministere de l'Enseignement Superieur et de la Recherche
  5. Partner University Fund

Ask authors/readers for more resources

Rett syndrome and its early-onset seizure variant are severe neurodevelopmental disorders associated with mutations within the MECP2 and the CDKL5 genes. Antidepressants and drugs of abuse induce the expression of the epigenetic factor MeCP2, thereby influencing chromatin remodeling. We show that increased MeCP2 levels resulted in the repression of Cdk15 in rat brain structures in response to cocaine, as well as in cells exposed to serotonin, or overexpressing MeCP2. In contrast, Cdk15 was induced by siRNA-mediated knockdown of Mecp2 and by DNA-methyltransferase inhibitors, demonstrating its regulation by MeCP2 and by DNA methylation. Cdk15 gene methylation and its methylation-dependent binding to MeCP2 were increased in the striatum of cocaine-treated rats. Our data demonstrate that Cdk15 is a MeCP2-repressed target gene providing a link between genes the mutation of which generates overlapping symptoms. They highlight DNA methylation changes as a potential mechanism participating in the long-term plasticity triggered by pharmacological agents. (C) 2010 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available